Sanofi Gets EU Backing for New Attempt at 6-in-1 Child Vaccine

Sanofi won European Union regulatory backing for its six-in-one children’s vaccine, the French drugmaker’s second attempt at such a product and part of a plan to grow in a market dominated by GlaxoSmithKline Plc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.